{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:41:38Z","timestamp":1791204098640,"version":"4.2.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0021772","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T17:02:41Z","timestamp":1309539761000},"page":"e21772","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":80,"title":["Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis"],"prefix":"10.1371","volume":"6","author":[{"given":"Maria C.","family":"Lebre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa E.","family":"Vergunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy Y. K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efda","family":"Aarrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana S. F.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wyant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Horuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris A.","family":"Reedquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/1529-0131(200105)44:5<1022::AID-ANR181>3.0.CO;2-N","article-title":"Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes\/macrophages in rheumatoid arthritis.","volume":"44","author":"KJ Katschke Jr","year":"2001","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/ard.2004.020529","article-title":"Chemokines in joint disease: the key to inflammation?","volume":"63","author":"JJ Haringman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/art.1780400206","article-title":"Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.","volume":"40","author":"PP Tak","year":"1997","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1002\/art.22964","article-title":"Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker.","volume":"56","author":"CA Wijbrandts","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/ar2333","article-title":"Cells of the synovium in rheumatoid arthritis. Macrophages.","volume":"9","author":"RW Kinne","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.24505","article-title":"The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases.","volume":"60","author":"JA Hamilton","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.18.1.593","article-title":"The role of chemokine receptors in primary, effector, and memory immune responses.","volume":"18","author":"F Sallusto","year":"2000","journal-title":"Annual Review of Immunology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.4049\/jimmunol.181.11.8053","article-title":"Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases.","volume":"181","author":"D Hartl","year":"2008","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/clim.2000.4957","article-title":"CXCR3 and CCR5 ligands in rheumatoid arthritis synovium.","volume":"98","author":"DD Patel","year":"2001","journal-title":"Clin Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/ard.2005.037176","article-title":"Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis.","volume":"65","author":"JJ Haringman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1046\/j.1365-2249.1996.d01-836.x","article-title":"The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines.","volume":"106","author":"J al-Mughales","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/clin.1998.4590","article-title":"RANTES expression and contribution to monocyte chemotaxis in arthritis.","volume":"89","author":"MV Volin","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1172\/JCI117097","article-title":"Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.","volume":"93","author":"AE Koch","year":"1994","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00109-005-0637-5","article-title":"The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis.","volume":"83","author":"MP Quinones","year":"2005","journal-title":"J Mol Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/art.20850","article-title":"Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.","volume":"52","author":"MP Vierboom","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/art.23591","article-title":"Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.","volume":"58","author":"CE Vergunst","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1002\/art.27652","article-title":"Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.","author":"DM Gerlag","year":"2010"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1136\/ard.2010.131235","article-title":"CCR5 blockade in rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial.","volume":"69","author":"AW van Kuijk","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/clin.1998.4590","article-title":"RANTES expression and contribution to monocyte chemotaxis in arthritis.","volume":"89","author":"MV Volin","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0165-2478(97)00075-8","article-title":"Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA\/1 mice.","volume":"57","author":"C Plater-Zyberk","year":"1997","journal-title":"Immunol Lett"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.62.8.715","article-title":"Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.","volume":"62","author":"JJ Haringman","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1002\/art.24978","article-title":"MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.","volume":"60","author":"CE Vergunst","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.2174\/156802610791561237","article-title":"CCR1 antagonists: what have we learned from clinical trials.","volume":"10","author":"RP Gladue","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","article-title":"Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.","volume":"184","author":"AM Grabiec","year":"2010","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.24505","article-title":"The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases.","volume":"60","author":"JA Hamilton","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/13543770802641346","article-title":"Chemokine receptor antagonists: Part 1.","volume":"19","author":"JE Pease","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/ar1172","article-title":"Chemokine blockade: a new era in the treatment of rheumatoid arthritis?","volume":"6","author":"JJ Haringman","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/art.20932","article-title":"Chemokines and their receptors in rheumatoid arthritis: future targets?","volume":"52","author":"AE Koch","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1517\/13543770802641353","article-title":"Chemokine receptor antagonists: part 2.","volume":"19","author":"JE Pease","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.","volume":"54","author":"JJ Haringman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nri2972","article-title":"Overcoming hurdles in developing successful drugs targeting chemokine receptors.","volume":"11","author":"TJ Schall","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/03009740701482800","article-title":"Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis.","volume":"36","author":"Z Jiao","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/art.23590","article-title":"Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?","volume":"58","author":"AE Proudfoot","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e7865","DOI":"10.1371\/journal.pone.0007865","article-title":"Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease.","volume":"4","author":"RM Thurlings","year":"2009","journal-title":"PLoS ONE"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/clpt.2011.33","article-title":"Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose.","volume":"89","author":"DJ Dairaghi","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0021772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T12:51:37Z","timestamp":1560343897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0021772"}},"subtitle":[],"editor":[{"given":"Joseph El","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0021772","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}